Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib

B Melosky, J Agulnik, H Assi - Current Oncology, 2008 - mdpi.com
Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and
chemotherapy have both demonstrated efficacy in recurrent metastatic non-small-cell lung …
被引用次数：29 相关文章

Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib.

B Melosky, J Agulnik, H Assi - Current Oncology (Toronto, Ont.), 2008 - europepmc.org
Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIS) and
chemotherapy have both demonstrated efficacy in recurrent metastatic non-small-cell lung …
[PDF] scienceopen.com

[PDF][PDF] Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib

B Melosky, J Agulnik, H Assi - CURRENT ONCOLOGY, 2008 - scienceopen.com
Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and
chemotherapy have both demonstrated efficacy in recurrent metastatic non-small-cell lung …
[PDF] researchgate.net

[PDF][PDF] Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib

B Melosky, J Agulnik, H Assi - CURRENT ONCOLOGY, 2008 - researchgate.net
Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and
chemotherapy have both demonstrated efficacy in recurrent metastatic non-small-cell lung …
[PDF] academia.edu

[PDF][PDF] Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib

B Melosky, J Agulnik, H Assi - CURRENT ONCOLOGY, 2008 - academia.edu
Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and
chemotherapy have both demonstrated efficacy in recurrent metastatic non-small-cell lung …
[PDF] semanticscholar.org

[PDF][PDF] Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib

B Melosky, J Agulnik, H Assi - CURRENT ONCOLOGY, 2008 - pdfs.semanticscholar.org
Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and
chemotherapy have both demonstrated efficacy in recurrent metastatic non-small-cell lung …

Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib

B Melosky, J Agulnik, H Assi - … oncology (Toronto, Ont …, 2008 - pubmed.ncbi.nlm.nih.gov
Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIS) and
chemotherapy have both demonstrated efficacy in recurrent metastatic non-small-cell lung …
[PDF] psu.edu

[PDF][PDF] Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib

B Melosky, J Agulnik, H Assi - CURRENT ONCOLOGY, 2008 - Citeseer
Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and
chemotherapy have both demonstrated efficacy in recurrent metastatic non-small-cell lung …
[HTML] nih.gov

[HTML][HTML] Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib

B Melosky, J Agulnik, H Assi - Current Oncology, 2008 - ncbi.nlm.nih.gov
Background Epidermal growth factor receptor tyrosine kinase inhibitors (egfr-tkis) and
chemotherapy have both demonstrated efficacy in recurrent metastatic non-small-cell lung …